PRESS RELEASE : MorphoSys To Present At the 39th Annual J.P. Morgan Healthcare Conference

 
 DGAP-News: MorphoSys AG / Key word(s): Conference 
MorphoSys To Present At the 39th Annual J.P. Morgan Healthcare Conference 
 
2021-01-11 / 08:00 
The issuer is solely responsible for the content of this announcement. 
 
*Media Release* 
Planegg/Munich, Germany, January 11, 2021 
 
*MorphoSys To Present At the 39th Annual J.P. Morgan Healthcare Conference* 
 
MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR), 
a commercial-stage biopharmaceutical company and a leader in antibody, 
protein and peptide technologies, announced today that Jean-Paul Kress, 
M.D., Chief Executive Officer of MorphoSys, will present at the 39th Annual 
J.P. Morgan Healthcare Conference on Wednesday January 13 at 2:50 p.m. EST. 
 
Live audio of the presentation can be accessed from the Media and Investors 
section under Conferences on MorphoSys' website, www.morphosys.com [1]. The 
presentation as well as a replay of the webcast will also be available on 
MorphoSys' website. 
 
*About MorphoSys* 
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the 
discovery, development and commercialization of innovative therapies for 
patients suffering from cancer and autoimmune diseases. Based on its leading 
expertise in antibody, protein and peptide technologies, MorphoSys, together 
with its partners, has developed and contributed to the development of more 
than 100 product candidates, of which 27 are currently in clinical 
development. In 2017, Tremfya(R), developed by Janssen Research & 
Development, LLC and marketed by Janssen Biotech, Inc., for the treatment of 
plaque psoriasis, became the first drug based on MorphoSys' antibody 
technology to receive regulatory approval. In July 2020, the U.S. Food and 
Drug Administration (FDA) granted accelerated approval of the company's 
proprietary product Monjuvi(R) (tafasitamab-cxix) in combination with 
lenalidomide in patients with a certain type of lymphoma. 
 
Headquartered near Munich, Germany, the MorphoSys group, including the fully 
owned U.S. subsidiary MorphoSys US Inc., has more than 600 employees. More 
information at www.morphosys.com [1] or www.morphosys-us.com [2]. 
 
Monjuvi(R) is a registered trademark of MorphoSys AG. 
Tremfya(R) is a registered trademark of Janssen Biotech, Inc. 
 
*MorphoSys Forward-Looking Statements* 
This communication contains certain forward-looking statements concerning 
the MorphoSys group of companies, including the expectations regarding 
Monjuvi's ability to treat patients with relapsed or refractory diffuse 
large B-cell lymphoma, the further clinical development of tafasitamab-cxix, 
including ongoing confirmatory trials, additional interactions with 
regulatory authorities and expectations regarding future regulatory filings 
and possible additional approvals for tafasitamab-cxix as well as the 
commercial performance of Monjuvi. The words "anticipate," "believe," 
"estimate," "expect," "intend," "may," "plan," "predict," "project," 
"would," "could," "potential," "possible," "hope" and similar expressions 
are intended to identify forward-looking statements, although not all 
forward-looking statements contain these identifying words. The 
forward-looking statements contained herein represent the judgment of 
MorphoSys as of the date of this release and involve known and unknown risks 
and uncertainties, which might cause the actual results, financial condition 
and liquidity, performance or achievements of MorphoSys, or industry 
results, to be materially different from any historic or future results, 
financial conditions and liquidity, performance or achievements expressed or 
implied by such forward-looking statements. In addition, even if MorphoSys' 
results, performance, financial condition and liquidity, and the development 
of the industry in which it operates are consistent with such 
forward-looking statements, they may not be predictive of results or 
developments in future periods. Among the factors that may result in 
differences are MorphoSys' expectations regarding risks and uncertainties 
related to the impact of the COVID-19 pandemic to MorphoSys' business, 
operations, strategy, goals and anticipated milestones, including its 
ongoing and planned research activities, ability to conduct ongoing and 
planned clinical trials, clinical supply of current or future drug 
candidates, commercial supply of current or future approved products, and 
launching, marketing and selling current or future approved products, the 
global collaboration and license agreement for tafasitamab, the further 
clinical development of tafasitamab, including ongoing confirmatory trials, 
and MorphoSys' ability to obtain and maintain requisite regulatory approvals 
and to enroll patients in its planned clinical trials, additional 
interactions with regulatory authorities and expectations regarding future 
regulatory filings and possible additional approvals for tafasitamab-cxix as 
well as the commercial performance of Monjuvi, MorphoSys' reliance on 
collaborations with third parties, estimating the commercial potential of 
its development programs and other risks indicated in the risk factors 
included in MorphoSys' Annual Report on Form 20-F and other filings with the 
U.S. Securities and Exchange Commission. Given these uncertainties, the 
reader is advised not to place any undue reliance on such forward-looking 
statements. These forward-looking statements speak only as of the date of 
publication of this document. MorphoSys expressly disclaims any obligation 
to update any such forward-looking statements in this document to reflect 
any change in its expectations with regard thereto or any change in events, 
conditions or circumstances on which any such statement is based or that may 
affect the likelihood that actual results will differ from those set forth 
in the forward-looking statements, unless specifically required by law or 
regulation. 
 
_For more information, please contact:_ 
 
*Media Contacts:*             *Investor Contacts:* 
Thomas Biegi                  Dr. Julia Neugebauer 
Vice President                Senior Director 
Tel.: +49 (0)89 / 89927 26079 Tel: +49 (0)89 / 899 27 179 
[e-mail]    [e-mail] 
Jeanette Bressi               Myles Clouston 
Director, US Communications   Senior Director 
Tel: [phone]          Tel: [phone] 
[e-mail] [e-mail] 
 
2021-01-11 Dissemination of a Corporate News, transmitted by DGAP - a 
service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
 
The DGAP Distribution Services include Regulatory Announcements, 
Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
Language:    English 
Company:     MorphoSys AG 
             Semmelweisstr. 7 
             82152 Planegg 
             Germany 
Phone:       [phone] 
Fax:         [phone] 
E-mail:      [e-mail] 
Internet:    www.morphosys.com 
ISIN:        DE0006632003 
WKN:         663200 
Indices:     MDAX, TecDAX 
Listed:      Regulated Market in Frankfurt (Prime Standard); Regulated 
             Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, 
             Munich, Stuttgart, Tradegate Exchange; Nasdaq 
EQS News ID: 1159546 
 
End of News DGAP News Service 
 
1159546 2021-01-11 
 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=af6b62de1fd30b6c8f4ab4736ef0907c&application_id=1159546&site_id=vwd&application_name=news 
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=cd1c46e7059c943c127d3d712e7da310&application_id=1159546&site_id=vwd&application_name=news

(END) Dow Jones Newswires

January 11, 2021 02:00 ET (07:00 GMT)